SEC Form 4 · accession 0001209191-18-054504
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deborah A Griffin
Officer — Chief Accounting Officer
Period of report
Mar 2, 2018
Accepted (ET)
Oct 9, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1,F2 | $19.16 | Mar 2, 2018 | A | 30,002 | A | — | Mar 2, 2028 | Ordinary Shares | 30,002 | 30,002 | D |
| Restricted Share UnitsF3,F4,F2 | — | Mar 2, 2018 | A | 11,764 | A | — | — | Ordinary Shares | 11,764 | 11,764 | D |
Explanation of responses
- F1Stock options were granted on March 2, 2018, with 7,500 vesting on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 7,502 vesting on March 2, 2022.
- F2The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F3Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F4Restricted share units were granted on March 2, 2018, with 2,941 vesting on each of March 2, 2019, March 2, 2020, March 2, 2021 and March 2, 2022.